GB201209096D0 - Compounds - Google Patents

Compounds

Info

Publication number
GB201209096D0
GB201209096D0 GBGB1209096.5A GB201209096A GB201209096D0 GB 201209096 D0 GB201209096 D0 GB 201209096D0 GB 201209096 A GB201209096 A GB 201209096A GB 201209096 D0 GB201209096 D0 GB 201209096D0
Authority
GB
United Kingdom
Prior art keywords
compounds
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB1209096.5A
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
LifeArc
Original Assignee
Medical Research Council Technology
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=46546551&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=GB201209096(D0) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Medical Research Council Technology filed Critical Medical Research Council Technology
Priority to GBGB1209096.5A priority Critical patent/GB201209096D0/en
Publication of GB201209096D0 publication Critical patent/GB201209096D0/en
Priority to SG11201407053YA priority patent/SG11201407053YA/en
Priority to HK15104401.8A priority patent/HK1203974B/en
Priority to JP2015513275A priority patent/JP6411998B2/ja
Priority to HRP20191293TT priority patent/HRP20191293T1/hr
Priority to MEP-2019-181A priority patent/ME03393B/me
Priority to DK19163818.8T priority patent/DK3521315T3/da
Priority to SM20210014T priority patent/SMT202100014T1/it
Priority to ES13730049T priority patent/ES2728856T3/es
Priority to AU2013265025A priority patent/AU2013265025B2/en
Priority to PT191638188T priority patent/PT3521315T/pt
Priority to PL13730049T priority patent/PL2855530T3/pl
Priority to MX2014014264A priority patent/MX367517B/es
Priority to US14/402,675 priority patent/US10005846B2/en
Priority to DK13730049.7T priority patent/DK2855530T3/da
Priority to LTEP19163818.8T priority patent/LT3521315T/lt
Priority to PT13730049T priority patent/PT2855530T/pt
Priority to NZ701424A priority patent/NZ701424A/en
Priority to SI201331811T priority patent/SI3521315T1/sl
Priority to SM20190407T priority patent/SMT201900407T1/it
Priority to EP13730049.7A priority patent/EP2855530B1/en
Priority to MYPI2014003271A priority patent/MY185966A/en
Priority to HUE13730049A priority patent/HUE045539T2/hu
Priority to MA37670A priority patent/MA37670B1/fr
Priority to PE2014002040A priority patent/PE20150346A1/es
Priority to PCT/GB2013/051373 priority patent/WO2013175229A1/en
Priority to UAA201413832A priority patent/UA117657C2/uk
Priority to IN2231MUN2014 priority patent/IN2014MN02231A/en
Priority to CA2874488A priority patent/CA2874488C/en
Priority to SI201331487T priority patent/SI2855530T1/sl
Priority to PL19163818T priority patent/PL3521315T3/pl
Priority to KR1020147036419A priority patent/KR102091223B1/ko
Priority to TR2019/06781T priority patent/TR201906781T4/tr
Priority to RS20190909A priority patent/RS59135B1/sr
Priority to LTEP13730049.7T priority patent/LT2855530T/lt
Priority to RS20210033A priority patent/RS61286B1/sr
Priority to ES19163818T priority patent/ES2835383T3/es
Priority to HUE19163818A priority patent/HUE052490T2/hu
Priority to EA201492162A priority patent/EA036810B1/ru
Priority to BR112014029089-0A priority patent/BR112014029089B1/pt
Priority to CN201380026672.3A priority patent/CN104321346B/zh
Priority to EP19163818.8A priority patent/EP3521315B1/en
Priority to IL235369A priority patent/IL235369B/en
Priority to TN2014000458A priority patent/TN2014000458A1/fr
Priority to ZA2014/08213A priority patent/ZA201408213B/en
Priority to CL2014003125A priority patent/CL2014003125A1/es
Priority to PH12014502582A priority patent/PH12014502582B1/en
Priority to ECIEPI201430942A priority patent/ECSP14030942A/es
Priority to CO14281628A priority patent/CO7151528A2/es
Priority to US15/987,611 priority patent/US10961319B2/en
Priority to JP2018104139A priority patent/JP2018166510A/ja
Priority to CY20191100807T priority patent/CY1121932T1/el
Priority to US17/121,541 priority patent/US11718686B2/en
Priority to HRP20202059TT priority patent/HRP20202059T1/hr
Priority to CY20211100013T priority patent/CY1123926T1/el
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1075—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody the antibody being against an enzyme
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dermatology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Psychology (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Psychiatry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Optics & Photonics (AREA)
  • Physics & Mathematics (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Hematology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
GBGB1209096.5A 2012-05-24 2012-05-24 Compounds Ceased GB201209096D0 (en)

Priority Applications (55)

Application Number Priority Date Filing Date Title
GBGB1209096.5A GB201209096D0 (en) 2012-05-24 2012-05-24 Compounds
SG11201407053YA SG11201407053YA (en) 2012-05-24 2013-05-24 Anti -transglutaminase 2 antibodies
HK15104401.8A HK1203974B (en) 2012-05-24 2013-05-24 Anti -transglutaminase 2 antibodies
JP2015513275A JP6411998B2 (ja) 2012-05-24 2013-05-24 抗トランスグルタミナーゼ２抗体
HRP20191293TT HRP20191293T1 (hr) 2012-05-24 2013-05-24 Anti-transglutaminaza 2 antitijela
MEP-2019-181A ME03393B (me) 2012-05-24 2013-05-24 Anti-transglutaminazna 2 antitijela
DK19163818.8T DK3521315T3 (da) 2012-05-24 2013-05-24 Anti-transglutaminase-2-antistoffer
SM20210014T SMT202100014T1 (it) 2012-05-24 2013-05-24 Anticorpi anti-translutaminasi 2
ES13730049T ES2728856T3 (es) 2012-05-24 2013-05-24 Anticuerpos anti-transglutaminasa 2
AU2013265025A AU2013265025B2 (en) 2012-05-24 2013-05-24 Anti -transglutaminase 2 antibodies
PT191638188T PT3521315T (pt) 2012-05-24 2013-05-24 Anticorpos anti-transglutaminase 2
PL13730049T PL2855530T3 (pl) 2012-05-24 2013-05-24 Przeciwciała przeciwko transglutaminazie 2
MX2014014264A MX367517B (es) 2012-05-24 2013-05-24 Anticuerpos de anti- transglutaminasa 2.
US14/402,675 US10005846B2 (en) 2012-05-24 2013-05-24 Anti-transglutaminase 2 antibodies
DK13730049.7T DK2855530T3 (da) 2012-05-24 2013-05-24 Anti-transglutaminase 2-antistoffer
LTEP19163818.8T LT3521315T (lt) 2012-05-24 2013-05-24 Antikūnai prieš transglutaminazę 2
PT13730049T PT2855530T (pt) 2012-05-24 2013-05-24 Anticorpos anti-transglutaminase 2
NZ701424A NZ701424A (en) 2012-05-24 2013-05-24 Anti -transglutaminase 2 antibodies
SI201331811T SI3521315T1 (sl) 2012-05-24 2013-05-24 Protitelesa proti anti-transglutaminazi 2
SM20190407T SMT201900407T1 (it) 2012-05-24 2013-05-24 Anticorpi anti-transglutaminasi 2
EP13730049.7A EP2855530B1 (en) 2012-05-24 2013-05-24 Anti-transglutaminase 2 antibodies
MYPI2014003271A MY185966A (en) 2012-05-24 2013-05-24 Anti-transglutaminase 2 antibodies
HUE13730049A HUE045539T2 (hu) 2012-05-24 2013-05-24 Transzglutamináz 2 elleni antitestek
MA37670A MA37670B1 (fr) 2012-05-24 2013-05-24 Anticorps anti-transglutaminase 2
PE2014002040A PE20150346A1 (es) 2012-05-24 2013-05-24 Anticuerpos de anti-transglutaminasa 2
PCT/GB2013/051373 WO2013175229A1 (en) 2012-05-24 2013-05-24 Anti -transglutaminase 2 antibodies
UAA201413832A UA117657C2 (uk) 2012-05-24 2013-05-24 Антитіло до трансглютамінази 2 (tg2)
IN2231MUN2014 IN2014MN02231A (enExample) 2012-05-24 2013-05-24
CA2874488A CA2874488C (en) 2012-05-24 2013-05-24 Anti-transglutaminase 2 antibodies
SI201331487T SI2855530T1 (sl) 2012-05-24 2013-05-24 Protitelesa proti anti-transglutaminazi 2
PL19163818T PL3521315T3 (pl) 2012-05-24 2013-05-24 Przeciwciała przeciwko transglutaminazie 2
KR1020147036419A KR102091223B1 (ko) 2012-05-24 2013-05-24 항트랜스글루타미나제 2 항체
TR2019/06781T TR201906781T4 (tr) 2012-05-24 2013-05-24 Anti-transglutaminaz 2 antikorları.
RS20190909A RS59135B1 (sr) 2012-05-24 2013-05-24 Anti-transglutaminazna 2 antitela
LTEP13730049.7T LT2855530T (lt) 2012-05-24 2013-05-24 Anti-transglutaminazės 2 antikūnai
RS20210033A RS61286B1 (sr) 2012-05-24 2013-05-24 Anti-transglutaminazna 2 antitela
ES19163818T ES2835383T3 (es) 2012-05-24 2013-05-24 Anticuerpos anti-transglutaminasa 2
HUE19163818A HUE052490T2 (hu) 2012-05-24 2013-05-24 Transzglutamináz 2 elleni antitestek
EA201492162A EA036810B1 (ru) 2012-05-24 2013-05-24 Антитела к трансглютаминазе 2
BR112014029089-0A BR112014029089B1 (pt) 2012-05-24 2013-05-24 Anticorpo ou um fragmento de ligação de antígeno do mesmo, composto, uso e seu método de produção
CN201380026672.3A CN104321346B (zh) 2012-05-24 2013-05-24 抗转谷氨酰胺酶2型的抗体
EP19163818.8A EP3521315B1 (en) 2012-05-24 2013-05-24 Anti-transglutaminase 2 antibodies
IL235369A IL235369B (en) 2012-05-24 2014-10-28 Anti-transglutaminase 2 antibodies
TN2014000458A TN2014000458A1 (en) 2012-05-24 2014-10-28 Anti -transglutaminase 2 antibodies
ZA2014/08213A ZA201408213B (en) 2012-05-24 2014-11-10 Anti-transglutaminase 2 antibodies
CL2014003125A CL2014003125A1 (es) 2012-05-24 2014-11-18 Anticuerpos de anti-transglutaminasa 2
PH12014502582A PH12014502582B1 (en) 2012-05-24 2014-11-19 Anti-TG2 Antibodies and Methods for Using the Same
ECIEPI201430942A ECSP14030942A (es) 2012-05-24 2014-12-12 Anticuerpos de anti-transglutaminasa 2
CO14281628A CO7151528A2 (es) 2012-05-24 2014-12-23 Anticuerpos de anti-transglutaminasa 2
US15/987,611 US10961319B2 (en) 2012-05-24 2018-05-23 Anti-transglutaminase 2 antibodies
JP2018104139A JP2018166510A (ja) 2012-05-24 2018-05-30 抗トランスグルタミナーゼ２抗体
CY20191100807T CY1121932T1 (el) 2012-05-24 2019-07-29 Αντισωματα κατα της τρανσγλουταμινασης 2
US17/121,541 US11718686B2 (en) 2012-05-24 2020-12-14 Anti-transglutaminase 2 antibodies
HRP20202059TT HRP20202059T1 (hr) 2012-05-24 2020-12-23 Anti-transglutaminaza 2 antitijela
CY20211100013T CY1123926T1 (el) 2012-05-24 2021-01-11 Αντισωματα κατα της τρανσγλουταμινασης 2

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB1209096.5A GB201209096D0 (en) 2012-05-24 2012-05-24 Compounds

Publications (1)

Publication Number Publication Date
GB201209096D0 true GB201209096D0 (en) 2012-07-04

Family

ID=46546551

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB1209096.5A Ceased GB201209096D0 (en) 2012-05-24 2012-05-24 Compounds

Country Status (39)

Country Link
US (3) US10005846B2 (enExample)
EP (2) EP3521315B1 (enExample)
JP (2) JP6411998B2 (enExample)
KR (1) KR102091223B1 (enExample)
CN (1) CN104321346B (enExample)
AU (1) AU2013265025B2 (enExample)
BR (1) BR112014029089B1 (enExample)
CA (1) CA2874488C (enExample)
CL (1) CL2014003125A1 (enExample)
CO (1) CO7151528A2 (enExample)
CY (2) CY1121932T1 (enExample)
DK (2) DK2855530T3 (enExample)
EA (1) EA036810B1 (enExample)
EC (1) ECSP14030942A (enExample)
ES (2) ES2728856T3 (enExample)
GB (1) GB201209096D0 (enExample)
HR (2) HRP20191293T1 (enExample)
HU (2) HUE052490T2 (enExample)
IL (1) IL235369B (enExample)
IN (1) IN2014MN02231A (enExample)
LT (2) LT2855530T (enExample)
MA (1) MA37670B1 (enExample)
ME (1) ME03393B (enExample)
MX (1) MX367517B (enExample)
MY (1) MY185966A (enExample)
NZ (1) NZ701424A (enExample)
PE (1) PE20150346A1 (enExample)
PH (1) PH12014502582B1 (enExample)
PL (2) PL2855530T3 (enExample)
PT (2) PT3521315T (enExample)
RS (2) RS61286B1 (enExample)
SG (1) SG11201407053YA (enExample)
SI (2) SI2855530T1 (enExample)
SM (2) SMT202100014T1 (enExample)
TN (1) TN2014000458A1 (enExample)
TR (1) TR201906781T4 (enExample)
UA (1) UA117657C2 (enExample)
WO (1) WO2013175229A1 (enExample)
ZA (1) ZA201408213B (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110055235A (zh) * 2019-05-14 2019-07-26 深圳市亚辉龙生物科技股份有限公司 用于转谷氨酰胺酶抗体检测的抗原及其制备方法、试剂盒及检测方法
FR3117599B1 (fr) * 2020-12-16 2024-11-29 Oreal Méthode de pronostic et/ou de diagnostic d’un état pelliculaire du cuir chevelu
GB202115127D0 (en) 2021-10-21 2021-12-08 Ucb Biopharma Sprl Formulations
GB202115121D0 (en) 2021-10-21 2021-12-08 Ucb Biopharma Sprl Formulations
GEP20257838B (en) 2021-11-18 2025-12-10 UCB Biopharma SRL Method for the treatment of progressive chronic interstitial lung disease
GB202116665D0 (en) 2021-11-18 2022-01-05 UCB Biopharma SRL Method for the treatment of a scleroderma disease
GB202118010D0 (en) 2021-12-13 2022-01-26 UCB Biopharma SRL Method for detecting and/or quantifying crosslinks formed by transglutaminases
CN116515786B (zh) * 2023-04-26 2024-05-28 广东医科大学 一种人tgm3乙酰化多肽、抗原、抗体及其制备方法和应用
WO2025153465A1 (en) 2024-01-15 2025-07-24 UCB Biopharma SRL Method for the treatment of fibrotic-related disorder associated to ibd

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4912120A (en) 1986-03-14 1990-03-27 Syntex (U.S.A.) Inc. 3,5-substituted 4,5-dihydroisoxazoles as transglutaminase inhibitors
AU1268192A (en) 1991-01-04 1992-08-17 Board Of Regents, The University Of Texas System Cloning and expression of tissue transglutaminases
AU6620596A (en) 1996-07-25 1998-02-20 Victoria University Of Manchester, The Use of transglutaminase modulators to promote wound healing
GB0103024D0 (en) 2001-02-07 2001-03-21 Rsr Ltd Assay for Autoantibodies to tissue transglutaminase
WO2004069175A2 (en) 2003-02-02 2004-08-19 Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services METHODS AND COMPOSITIONS FOR THE TREATMENT OF PARKINSON’S DISEASE AND OTHER α-SYNUCLEINOPATHIES
GB0314262D0 (en) 2003-06-19 2003-07-23 Univ Nottingham Trent Novel compounds and methods of using the same
WO2006100679A2 (en) * 2005-03-22 2006-09-28 Quark Pharmaceuticals, Inc. Recombinant antibodies against human type ii transglutaminase and uses thereof
WO2008063760A2 (en) 2006-10-18 2008-05-29 The University Of Texas M.D. Anderson Cancer Center Methods for treating cancer targeting transglutaminase
AU2009238897B2 (en) * 2008-04-24 2015-03-19 Gene Techno Science Co., Ltd. Humanized antibodies specific for amino acid sequence RGD of an extracellular matrix protein and the uses thereof
NZ595731A (en) 2009-03-19 2013-09-27 Univ Queensland Targets for growth factor signalling and methods of therapy
HU0900195D0 (en) 2009-04-01 2009-06-29 Debreceni Egyetem Diagnosis and treatment of gluten-induced autoimmune diseases
HU0900199D0 (en) * 2009-04-01 2009-06-29 Debreceni Egyetem Diagnosis of gluten-induced autoimmune diseases
WO2011151395A2 (en) 2010-06-02 2011-12-08 INSERM (Institut National de la Santé et de la Recherche Médicale) Transglutaminase 2 inhibitors for use in the prevention or treatment of rapidly progressive glomerulonephritis
GB2490655A (en) 2011-04-28 2012-11-14 Univ Aston Modulators of tissue transglutaminase

Also Published As

Publication number Publication date
TR201906781T4 (tr) 2019-05-21
SMT201900407T1 (it) 2019-09-09
BR112014029089A2 (pt) 2019-06-25
KR102091223B1 (ko) 2020-03-20
CA2874488C (en) 2021-09-07
RS61286B1 (sr) 2021-02-26
NZ701424A (en) 2016-08-26
US20210101999A1 (en) 2021-04-08
JP6411998B2 (ja) 2018-10-24
PT2855530T (pt) 2019-07-08
SMT202100014T1 (it) 2021-03-15
ECSP14030942A (es) 2015-09-30
TN2014000458A1 (en) 2016-03-30
ES2835383T3 (es) 2021-06-22
CN104321346A (zh) 2015-01-28
SI3521315T1 (sl) 2020-12-31
PE20150346A1 (es) 2015-03-05
EA036810B1 (ru) 2020-12-23
IN2014MN02231A (enExample) 2015-07-24
US20180355060A1 (en) 2018-12-13
CY1121932T1 (el) 2020-10-14
EP2855530A1 (en) 2015-04-08
ZA201408213B (en) 2020-02-26
UA117657C2 (uk) 2018-09-10
EP3521315A1 (en) 2019-08-07
CL2014003125A1 (es) 2015-08-21
SG11201407053YA (en) 2014-12-30
PL2855530T3 (pl) 2019-10-31
HK1203974A1 (en) 2015-11-06
RS59135B1 (sr) 2019-09-30
MA37670A1 (fr) 2016-05-31
CO7151528A2 (es) 2014-12-29
HRP20191293T1 (hr) 2019-10-18
BR112014029089B1 (pt) 2023-04-25
SI2855530T1 (sl) 2019-08-30
US10005846B2 (en) 2018-06-26
EA201492162A1 (ru) 2015-03-31
MA37670B1 (fr) 2019-12-31
DK2855530T3 (da) 2019-06-24
ME03393B (me) 2020-01-20
MY185966A (en) 2021-06-14
PL3521315T3 (pl) 2021-08-23
EP2855530B1 (en) 2019-05-01
IL235369B (en) 2019-05-30
HRP20202059T1 (hr) 2021-02-19
HUE045539T2 (hu) 2019-12-30
AU2013265025B2 (en) 2018-04-26
LT3521315T (lt) 2020-12-28
ES2728856T3 (es) 2019-10-29
US11718686B2 (en) 2023-08-08
CY1123926T1 (el) 2022-05-27
IL235369A0 (en) 2014-12-31
HUE052490T2 (hu) 2021-04-28
DK3521315T3 (da) 2020-11-09
EP3521315B1 (en) 2020-10-14
WO2013175229A1 (en) 2013-11-28
PH12014502582A1 (en) 2015-01-21
KR20150013340A (ko) 2015-02-04
CA2874488A1 (en) 2013-11-28
JP2018166510A (ja) 2018-11-01
US10961319B2 (en) 2021-03-30
AU2013265025A1 (en) 2014-12-04
PT3521315T (pt) 2020-10-29
MX2014014264A (es) 2015-05-15
US20150218289A1 (en) 2015-08-06
JP2015519897A (ja) 2015-07-16
MX367517B (es) 2019-08-26
PH12014502582B1 (en) 2015-01-21
CN104321346B (zh) 2018-12-07
LT2855530T (lt) 2019-07-25

Similar Documents

Publication Publication Date Title
IL268013A (en) Tetrahydropyrazolopyrimidine compounds
AP2014007810A0 (en) Imidazopyrrolidinone compounds
IL237341A0 (en) Compounds that promote neurogenesis
GB201209138D0 (en) Compounds
GB201214750D0 (en) Compounds
GB201215357D0 (en) Compounds
EP2828262A4 (en) IMIDAZOTRIAZINONVERBINDUNGEN
GB201204985D0 (en) Compounds
GB201204125D0 (en) Compounds
ZA201500778B (en) Compounds
PL2836495T3 (pl) Związki tetrahydropirolotiazynowe
GB201209096D0 (en) Compounds
GB201219820D0 (en) Compounds
GB201217310D0 (en) Compounds
GB201223429D0 (en) Compounds
GB201220029D0 (en) Compounds
GB201219819D0 (en) Compounds
GB201218799D0 (en) Compounds
GB201218774D0 (en) Compounds
GB201218776D0 (en) Compounds
GB201218758D0 (en) Compounds
GB201218018D0 (en) Compounds
GB201217290D0 (en) Compounds
GB201217312D0 (en) Compounds
GB201217311D0 (en) Compounds

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)